A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

Abbott Laboratories (ABT) has drawn fresh attention after unveiling Libre Assist, an AI driven feature in its Libre app that ...

Abbott Laboratories posted its largest-ever quarter for rapid diagnostics, according to a news release from data analytics and consulting firm GlobalData. The company’s rapid diagnostics segment sold ...

Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.

Wednesday, Abbott Laboratories (NYSE:ABT) reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion. Reported ...

Abbott Laboratories ABT has witnessed strong momentum in the past year. Shares of the company have risen 12.7% compared with the 9% growth of the industry during the same time frame. The S&P 500 ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties.

Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, ...

Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.

In 2013, Abbott Labs shifted to focus on generics, medical devices, diagnostics, and nutrition. Since then, it has grown its business and become much more robust and diverse. While it has benefited ...